EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CCR5 and IL-12 co-expression in CAR T cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors

Yonggui Tian, Liubo Zhang, Yu Ping, Zhen Zhang, Chang Yao, Chunyi Shen, Feng Li, Chunli Wen, Yi Zhang

Cancer Immunology, Immunotherapy · 03.01.2025 · 74 (2)

DOI: 10.1007/s00262-024-03909-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 03.01.2025. Verfasst von Yonggui Tian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Receptors, CCR5, Interleukin-12, Immunotherapy, Adoptive. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Intergovernmental International Science and Technology Innovation Cooperation Project, Project of Central Leading Local Science and Technology Development of Henan Province, Medical Science and Technology Project of Henan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T cell therapy for solid tumors faces significant challenges, including inadequate infiltration, limited proliferation, diminished effector function of CAR T cells, and an immunosuppressive tumor microenvironment (TME). In this study, we utilized The Cancer Genome Atlas database to identify key chemokines (CCL4, CCL5, and CCR5) associated with T cell infiltration across various solid tumor types. The CCL4/CCL5-CCR5 axis emerged as significantly correlated with the presence of T cells within tumors, and enhancing the expression of CCR5 in CAR T cells bolstered their migratory capacity. Furthermore, single-cell immunoprofiling of tumor tissues revealed that macrophages within the TME primarily interact with CD8+ T cells, impeding their tumor response. However, CAR T cells engineered to secrete Interleukin (IL)-12 can counteract macrophage-mediated immunosuppression and augment T cell functionality. To address these obstacles, we employed esophageal carcinoma as a model to develop mesothelin-targeted CAR T cells co-expressing CCR5 and IL-12 (CARTmeso-5-12), subsequently assessing their antitumor capabilities in vitro and in vivo. The CARTmeso-5-12 cells demonstrated enhanced tumor infiltration due to overexpression of CCR5, and IL-12 secretion further amplified CAR T cell efficacy by attenuating the suppressive influence of tumor-infiltrating macrophages, thus improving tumor eradication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentReceptors, CCR5Interleukin-12Immunotherapy, AdoptiveReceptors, Chimeric AntigenHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysNeoplasmsLymphocytes, Tumor-InfiltratingFemaleMacrophagesCD8-Positive T-LymphocytesMesothelin

Stichwörter der Autor:innen

CAR T cellsCCR5IL-12Tumor Mircoenvironment

Substanzen

Receptors, CCR5Interleukin-12Receptors, Chimeric AntigenCCR5 protein, humanMesothelin

Autor:innen und Institutionen

  • Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
  • Department of Laboratory Medicine, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, 450052, Henan, China.
  • Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. yizhang@zzu.edu.cn.
  • State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, 450052, Henan, China. yizhang@zzu.edu.cn.
  • Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China. yizhang@zzu.edu.cn.

Förderung

  • Intergovernmental International Science and Technology Innovation Cooperation Project
  • Project of Central Leading Local Science and Technology Development of Henan Province
  • Medical Science and Technology Project of Henan Province
  • the National Natural Science Foundation of China

Zitieren

APA

Tian, Y., Zhang, L., Ping, Y., Zhang, Z., Yao, C., Shen, C., Li, F., Wen, C., & Zhang, Y. (2025). CCR5 and IL-12 co-expression in CAR T cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors. Cancer Immunology, Immunotherapy, 74(2). https://doi.org/10.1007/s00262-024-03909-w

Vancouver

Tian Y, Zhang L, Ping Y, Zhang Z, Yao C, Shen C, et al. CCR5 and IL-12 co-expression in CAR T cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors. Cancer Immunology, Immunotherapy. 2025;74(2). doi:10.1007/s00262-024-03909-w

BibTeX
@article{Tian2025,
  author = {Tian, Yonggui and Zhang, Liubo and Ping, Yu and Zhang, Zhen and Yao, Chang and Shen, Chunyi and Li, Feng and Wen, Chunli and Zhang, Yi},
  title = {CCR5 and IL-12 co-expression in CAR T cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  volume = {74},
  number = {2},
  doi = {10.1007/s00262-024-03909-w}
}
Kostenlos starten →